The design history record was reviewed for lot 21c1004 and indicated no abnormal processing.The lot in question met all specifications prior to its release.There have been no ncrs or capas associated with this lot.Cerapedics risk analysis document (b)(4), revision 23 (putty) was reviewed.The failure mode identified in this complaint is already identified under line item 38 (potential effect 2) - "inadequate retention in graft site, migration." therefore, no updates to the risk assessment are required.There have been 9 (nine) previous complaints related to this potential failure mode.Based on the total number of units distributed (n=265,783), the observed rate is (b)(4).The mitigated risk probability for this potential failure mode is estimated to be 1 or an estimated occurrence rate of (b)(4) therefore, the benefit-risk analysis remains unchanged.Ous putty ifu (p/n 40002-01-10) lists the following as a potential adverse effect: "extrusion or migration of the bone void filler, as is possible with any bone void filler, resulting in pain, neural impingement, physical impairment, irritation or wear of an articulating joint, or loss of function; any of which my require revision surgery." as such, no updates are required for the ifu.
|